Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.

Autor: Mason M; Bristol Myers Squibb, Princeton, NJ, USA., Lapuente-Santana Ó; Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands., Halkola AS; Department of Mathematics and Statistics, University of Turku, Turku, Finland., Wang W; Faculty of Medicine, Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Mall R; Qatar Computing Research Institute, Hamad Bin Khalifa University, P.O. Box 34110, Doha, Qatar.; Department of Immunology, St. Jude Children's Research Hospital, P.O. Box 38105, Memphis, TN, USA.; Biotechnology Research Center, Technology Innovation Institute, P.O. Box 9639, Abu Dhabi, United Arab Emirates., Xiao X; School of Informatics, Xiamen University, Xiamen, China.; National Institute for Data Science in Health and Medicine, Xiamen University, Xiamen, China., Kaufman J; Department of Medicine, Duke University, Durham, NC, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Fu J; Dana-Farber Cancer Institute, Boston, MA, USA., Pfeil J; AbbVie, South San Francisco, CA, USA., Banerjee J; Sage Bionetworks, Seattle, WA, USA., Chung V; Sage Bionetworks, Seattle, WA, USA., Chang H; Bristol Myers Squibb, Princeton, NJ, USA., Chasalow SD; Bristol Myers Squibb, Princeton, NJ, USA., Lin HY; Bristol Myers Squibb, Princeton, NJ, USA., Chai R; Sage Bionetworks, Seattle, WA, USA., Yu T; Sage Bionetworks, Seattle, WA, USA., Finotello F; Institute of Molecular Biology, University of Innsbruck, Innsbruck, Austria.; Digital Science Center (DiSC), University of Innsbruck, Innsbruck, Austria., Mirtti T; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Department of Biomedical Engineering, School of Medicine, Emory University, Atlanta, GA, USA., Mäyränpää MI; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Bao J; Faculty of Medicine, Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland., Verschuren EW; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Ahmed EI; Human Immunology Department, Sidra Medicine, P.O. Box 26999, Doha, Qatar., Ceccarelli M; Department of Electrical Engineering and Information Technology (DIETI), University of Naples 'Federico II', 80125, Naples, Italy.; BIOGEM Institute of Molecular Biology and Genetics, Via Camporeale, Ariano Irpino, Italy., Miller LD; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA., Monaco G; BIOGEM Institute of Molecular Biology and Genetics, Via Camporeale, Ariano Irpino, Italy., Hendrickx WRL; Human Immunology Department, Sidra Medicine, P.O. Box 26999, Doha, Qatar.; College of Health and Life Sciences, Hamad Bin Khalifa University, P.O. Box 26999, Doha, Qatar., Sherif S; Human Immunology Department, Sidra Medicine, P.O. Box 26999, Doha, Qatar.; College of Health and Life Sciences, Hamad Bin Khalifa University, P.O. Box 26999, Doha, Qatar., Yang L; Dana-Farber Cancer Institute, Boston, MA, USA., Tang M; Dana-Farber Cancer Institute, Boston, MA, USA., Gu SS; Dana-Farber Cancer Institute, Boston, MA, USA., Zhang W; Dana-Farber Cancer Institute, Boston, MA, USA., Zhang Y; Dana-Farber Cancer Institute, Boston, MA, USA., Zeng Z; Dana-Farber Cancer Institute, Boston, MA, USA., Das Sahu A; Dana-Farber Cancer Institute, Boston, MA, USA., Liu Y; Dana-Farber Cancer Institute, Boston, MA, USA., Yang W; Aginome Scientific, Xiamen, China., Bedognetti D; Human Immunology Department, Sidra Medicine, P.O. Box 26999, Doha, Qatar.; College of Health and Life Sciences, Hamad Bin Khalifa University, P.O. Box 26999, Doha, Qatar.; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy., Tang J; Faculty of Medicine, Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Eduati F; Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.; Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Eindhoven, The Netherlands., Laajala TD; Department of Mathematics and Statistics, University of Turku, Turku, Finland.; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; FICAN West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.; Department of Pharmacology, Anschutz Medical Campus, University of Colorado, Denver, CO, USA., Geese WJ; Bristol Myers Squibb, Princeton, NJ, USA., Guinney J; Tempus Labs, Chicago, IL, USA., Szustakowski JD; Bristol Myers Squibb, Princeton, NJ, USA., Vincent BG; Department of Medicine, Division of Hematology, Department of Microbiology and Immunology, Curriculum in Bioinformatics and Computational Biology, Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Carbone DP; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. david.p.carbone@gmail.com.

Publikováno v: Journal of translational medicine [J Transl Med] 2024 Feb 21; Vol. 22 (1), pp. 190. Date of Electronic Publication: 2024 Feb 21.

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.

Autor: Ross-Macdonald P; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA., Walsh AM; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA., Chasalow SD; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA., Ammar R; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA., Papillon-Cavanagh S; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA., Szabo PM; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA., Choueiri TK; Department of Genitourinary Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA., Sznol M; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA., Wind-Rotolo M; Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA megan.windrotolo@bms.com.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Mar; Vol. 9 (3).

Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.

Autor: Postow MA; Department of Medicine, Memorial Sloan Kettering Cancer Center.; Weill Cornell Medical College, New York, New York., Chasalow SD; Bristol-Myers Squibb, Princeton, New Jersey, USA., Kuk D; Department of Medicine, Memorial Sloan Kettering Cancer Center., Panageas KS; Department of Medicine, Memorial Sloan Kettering Cancer Center., Cheng ML; Department of Medicine, Memorial Sloan Kettering Cancer Center., Yuan J; Department of Medicine, Memorial Sloan Kettering Cancer Center., Wolchok JD; Department of Medicine, Memorial Sloan Kettering Cancer Center.; Weill Cornell Medical College, New York, New York.

Publikováno v: Melanoma research [Melanoma Res] 2020 Feb; Vol. 30 (1), pp. 71-75.